The purpose of this study is to determine whether a pulsed magnetic field (PMF) pad will improve symptoms of rheumatoid arthritis (RA) in postmenopausal women.

Study hypothesis: A pulsed magnetic field pad will effectively reduce the symptoms of RA in postmenopausal women.

RA is a condition characterized by pain, fatigue, sleep disturbances, and mood changes. These symptoms often persist despite the use of nonsteroidal anti-inflammatory drugs (NSAIDs) and disease modifying antirheumatic drugs (DMARDs). Many women for whom these drugs do not work turn to complementary and alternative therapies, including the use of magnetic devices. Although few studies have investigated the effects of low strength PMF pads in persons with RA, evidence suggests that PMF may help relieve pain, inflammation, and fatigue. This study will determine the effects of a PMF device on RA symptoms in postmenopausal women.

This study will last 12 weeks. Participants will be randomly assigned to one of three groups: active PMF pad treatment, sham PMF pad treatment, or standard of care, which may include drug therapy or physical therapy. Participants in the active and sham PMF pad groups will be treated with their assigned pad for approximately 8 minutes, twice a day for the duration of the study. Questionnaires and self-report scales will be used to assess pain, fatigue, sleep quality, mood, and inflammation episodes. Blood and urine collection will occur to assess levels of stress hormones and certain proteins.

Ages Eligible for Study:  35 Years and above,  Genders Eligible for Study:  Female

Criteria

Inclusion Criteria:

• Diagnosis of RA
• Postmenopausal, defined by no menstrual period in at least 2 years prior to study entry or a hysterectomy
• Average pain of 2 or greater on a 0 to 10 pain scale
• Sleep difficulty
• Stable medication use related to RA for at least 4 weeks prior to study entry

Exclusion Criteria:

• Diagnoses of lupus, fibromyalgia, chronic fatigue syndrome, sleep apnea, or restless leg syndrome
• High-dose prednisone (more than 10 mg/day) or equivalent
• Currently undergoing hormone replacement therapy (HRT) or have stopped taking HRT less than 6 weeks prior to study entry
• Pacemakers or other implanted devices
• Epilepsy
• History of or present diagnosis of cancer